Companies to Watch: Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are emerging as a powerful platform for delivering highly targeted doses of oncology and potentially other drugs to patients with a minimum of side effects and toxicity.
Large pharmas are anxious to partner with or acquire ADC makers to access this technology — witness Pfizer’s $43 billion acquisition of Seagen Inc., AbbVie’s $10 billion acquisition of ImmunoGen and J&J’s $2 billion acquisition of Ambrx Biopharma – as they seek to replenish their oncology pipelines with next-generation targeted treatments.
The just-published Companies to Watch report from Clarivate identifies promising and as-yet under-the-radar ADC innovators. This report will highlight those picks and explore how ADC innovators and large pharmas alike can realize the greatest benefit for patients from this exciting technology.
Questions answered:
- What does the ADC landscape look like in terms of products and innovators?
- What are the ADC makers to watch?
- How can ADC makers future proof their products/platforms?
- How can ADC makers optimize their position in partnership and acquisition negotiations with large pharma?
- How can pharmas use RWD and AI/ML to conduct due diligence in pursuing ADC acquisitions?
